Search alternatives:
step decrease » sizes decrease (Expand Search), we decrease (Expand Search)
teer decrease » mean decrease (Expand Search), greater decrease (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
step decrease » sizes decrease (Expand Search), we decrease (Expand Search)
teer decrease » mean decrease (Expand Search), greater decrease (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
1581
-
1582
-
1583
-
1584
-
1585
-
1586
-
1587
-
1588
-
1589
-
1590
-
1591
-
1592
-
1593
-
1594
-
1595
Data_Sheet_1_Applying the Toyota production system to decrease the time required to transport patients undergoing surgery from the general ward to the operating room and reviewing...
Published 2022“…</p>Results<p>According to the original indicators, all goals were attained. “Total time spent” decreased by 62.3%. The time required for attendants to report to the nursing station decreased by 56.5%. …”
-
1596
Data_Sheet_2_Applying the Toyota production system to decrease the time required to transport patients undergoing surgery from the general ward to the operating room and reviewing...
Published 2022“…</p>Results<p>According to the original indicators, all goals were attained. “Total time spent” decreased by 62.3%. The time required for attendants to report to the nursing station decreased by 56.5%. …”
-
1597
-
1598
-
1599
-
1600
The effects of pretreatment with fingolimod-phosphate on BMECs in the presence of MS sera.
Published 2015“…Pretreatment with fingolimod-phosphate resulted in an increase in the claudin-5 protein levels (B) and TEER values (G) and a decrease in the VCAM-1 protein levels (F) in the BMECs, which were upregulated after exposure to the sera from all MS patients, including the RRMS-R, RRMS-S and SPMS patients, compared to that observed in the cells not pretreated with fingolimod-phosphate.…”